Event Details
January 01, 2018
Description
Expected FDA approval of a cannabis-derived pharmaceutical
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024725.jpg
This document is page 89 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It predicts legislative changes in 2018 for various states and analyzes the timeline for federal legalization based on public support data from Gallup. The document bears a 'HOUSE_OVERSIGHT_024725' Bates stamp, indicating it was part of a document production to the House Oversight Committee, though the content itself is a general market analysis rather than specific correspondence.
Related Events
Events with shared participants
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
FDA approval of Marinol and Cesamet
1985-01-01 • USA
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
FDA gave green light for Geron clinical trial.
2009-01-01 • US
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
FDA published industry guidance on botanical drug development.
2016-12-01 • USA
Previous FDA guidance on botanical drugs issued.
2004-06-01 • USA
FDA convened meeting to analyze drug data.
Date unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event